Biogazelle

Isis will provide Biogazelle with access to its antisense platform for the large-scale validation of therapeutic lncRNA targets from Biogazelle's target identification pipeline.

The accreditation is for the Belgian firm's mRNA, miRNA, and long non-coding RNA expression services.

NEW YORK (GenomeWeb) — Biogazelle said today that it has received a €2 million ($2.5 million) investment from Qbic Arkiv Fund, Foundation Majoie, and SOFI (Spin-Off Financing Instrument).

Core Life Sciences has signed a deal with Biogazelle that lets that company distribute qbase+, Core's software for analyzing qPCR data, in California.

Core Life Sciences said today that it has partnered with Belgium's Biogazelle to distribute its qbase+ qPCR software in California.

NEW YORK (GenomeWeb News) – Core Life Sciences announced this week that it and Biogazelle have reached an agreement to distribute Biogazelle's qbase+ software in California.

Belgium's Flanders Institute for Biotechnology, VIB, has licensed Biogazelle’s qbase+ software to support its real time PCR-based research projects.

BITS, the bioinformatics training and service facility of Belgium's Vlaams Instituut voor Biotechnologie, or VIB, will use Biogazelle's qbase+ software for PCR analysis, Biogazelle said this week.

Bio-Rad this week introduced qPCR assays and panels that have been wet-lab validated to meet the minimum information for publication of quantitative real-time PCR experiments, or MIQE, guidelines.

University of Rochester Medical Center said this week that Hulin Wu, a professor of biostatistics and computational biology, will serve as the founding director of its newly established Center for Integrative Bioinformatics and Experimental Mathematics.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.